# TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.

Study · id `cardio:ct-nct02653209` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02653209](<https://clinicaltrials.gov/study/NCT02653209>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02653209

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 525 participants.

## Technical summary

Registry record NCT02653209. Randomized; double masking; primary purpose treatment. Start 2016-11-01 (actual); primary completion 2021-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 525 participants (enrolled count; ClinicalTrials.gov record NCT02653209, source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)
- Started: 2016-11-01 (actual) (ClinicalTrials.gov record NCT02653209, source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)
- Primary completion: 2021-01 (actual) (ClinicalTrials.gov record NCT02653209, source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)
- Completion: 2021-01 (actual) (ClinicalTrials.gov record NCT02653209, source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT02653209, source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02653209-2021-04-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.
- Acronym: TriMaster
- Condition: Type 2 Diabetes
- Intervention (Drug): Sitagliptin - DPP4i
- Intervention (Drug): Canagliflozin - SGLT2i
- Intervention (Drug): Pioglitazone - TZD
- Lead sponsor: Royal Devon and Exeter NHS Foundation Trust
- Lead sponsor class: OTHER
- Collaborator: University of Exeter
- Collaborator class: OTHER
- Collaborator: NHS Tayside
- Collaborator class: OTHER\_GOV
- Collaborator: University of Dundee
- Collaborator class: OTHER
- Collaborator: University of Glasgow
- Collaborator class: OTHER
- Collaborator: Newcastle University
- Collaborator class: OTHER
- Collaborator: King's College London
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: University of Exeter (`cardio:org-university-of-exeter`)
- Registry lists this organization as a collaborator: University of Dundee (`cardio:org-university-of-dundee`)
- Registry lists this organization as a collaborator: University of Glasgow (`cardio:org-university-of-glasgow`)
- Registry lists this organization as a collaborator: Newcastle University (`cardio:org-newcastle-university`)
- Registry lists this organization as a collaborator: King's College London (`cardio:org-king-s-college-london`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study (`cardio:pubmed-36477733`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study (`cardio:pubmed-36477734`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 33a88175afdfde6bce6eb70e4dc3680a37d51cf857c1322ce5ccfadfb0d3de91
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
